Valuation: Penumbra, Inc.

Market Cap 12.67B 11.36B 10.47B 9.51B 18B 1,188B 18.5B 125B 49.96B 636B 47.55B 46.54B 2,012B P/E 2026 *
76.2x
P/E 2027 * 56.1x
Enterprise Value 12.22B 10.96B 10.1B 9.18B 17.37B 1,146B 17.85B 121B 48.2B 614B 45.88B 44.9B 1,941B EV / Sales 2026 *
7.61x
EV / Sales 2027 * 6.6x
Free-Float
97.05%
Yield 2026 *
-
Yield 2027 * -
1 day-0.13%
1 week+0.45%
Current month+0.79%
1 month+0.64%
3 months-1.39%
6 months-0.24%
Current year+3.39%
1 week 319
Extreme 319
324.76
1 month 316.35
Extreme 316.35
325.58
Current year 290
Extreme 290
362.41
1 year 274.2
Extreme 274.2001
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 57.85
Extreme 57.85
362.41
Manager TitleAgeSince
Chief Executive Officer 64 21/06/2004
President 41 01/09/2025
Director of Finance/CFO 54 02/12/2019
Director TitleAgeSince
Chairman 64 01/01/2015
Chairman 64 01/01/2005
Director/Board Member 59 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Tax

Chairperson

-1,367 0.0035%
15/09/26 Tax

Chairperson

-1,230 0.0031%
17/08/26 Free

Chairperson

3,060 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%+0.45%+18.82%+77.17% 12.67B
-1.24%+0.97%-12.26%+17.55% 191B
-1.27%+2.74%+9.64%+43.73% 124B
-1.83%+4.42%-8.66%+18.52% 123B
-2.99%-3.75%-42.30%+2.96% 96.14B
-0.72%+2.41%-4.37%+76.50% 66.54B
-0.38%+7.29%+17.05%-9.39% 57.91B
-1.22%+3.66%-1.82%+62.49% 54.89B
+1.47%-2.27%-4.29%+54.83% 49.1B
-5.16%-4.93%-2.50%-8.32% 36.19B
Average -1.28%+2.20%-3.07%+33.60% 81B
Weighted average by Cap. -1.35%+2.34%-7.07%+27.95%

Financials

2026 *2027 *
Net sales 1.61B 1.44B 1.33B 1.21B 2.28B 151B 2.35B 15.89B 6.33B 80.67B 6.03B 5.9B 255B 1.81B 1.62B 1.49B 1.36B 2.57B 170B 2.64B 17.89B 7.13B 90.83B 6.79B 6.64B 287B
Net income 178M 160M 147M 134M 253M 16.7B 260M 1.76B 702M 8.95B 669M 654M 28.29B 240M 215M 198M 180M 341M 22.52B 351M 2.38B 947M 12.06B 901M 882M 38.14B
Net Debt -446M -400M -368M -335M -633M -41.78B -651M -4.41B -1.76B -22.39B -1.67B -1.64B -70.77B -729M -653M -602M -547M -1.04B -68.32B -1.06B -7.21B -2.87B -36.6B -2.73B -2.68B -116B
Projected Income Statement - Annual - Penumbra, Inc.
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
11/11/26 $321.46 -0.12% 242,379
09/11/26 $321.85 +0.83% 251,285
06/11/26 $319.21 -0.59% 336,729
05/11/26 $321.11 -0.42% 310,538
04/11/26 $322.45 +0.76% 374,299
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Penumbra, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
321.46USD
Average target price
362.54USD
Spread / Average Target
+12.78%